Vagus nerve disorder

Summary

Vagus nerve disorder (MONDO:0001535) is a disease and 3 clinical trials. A subtype of glossopharyngeal nerve disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vagus nerve disorder
Mondo ID	MONDO:0001535
MeSH	D020421
DOID	DOID:12491
NCIT	C27591
SNOMED CT	73765005
UMLS	C0152179
MedGen	101824
Anatomy (UBERON)	UBERON:0001759
Is cancer (heuristic)	no

Also known as: disease of vagus nerve · disease or disorder of vagus nerve · disorder of pneumogastric [10th] nerve · disorder of vagus nerve · vagus nerve disease · vagus nerve disease or disorder · Vagus nerve disorder

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › glossopharyngeal nerve disorder › vagus nerve disorder

Related subtypes (4): glossopharyngeal nerve neoplasm, glossopharyngeal nerve paralysis, glossopharyngeal motor neuropathy, glossopharyngeal neuralgia

Subtypes (1): vagus nerve neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05664854	Not specified	RECRUITING	Electrical Impedance Tomography & Selective Stimulation of Vagus Nerve
NCT04192877	Not specified	COMPLETED	Validity and Inter-rater Reliability fo the Vagus Nerve Neurodynamic Test Among Healthy Subjects
NCT05918965	Not specified	UNKNOWN	Vagus Stimulation in Female Long COVID Patients.